Recursion Pharmaceuticals Inc’s recently made public that its Chief Executive Officer Gibson Christopher unloaded Company’s shares for reported $0.36 million on Apr 04 ’24. In the deal valued at $9.02 per share,40,000 shares were sold. As a result of this transaction, Gibson Christopher now holds 938,524 shares worth roughly $8.45 million.
Then, Gibson Christopher sold 25,000 shares, generating $225,500 in total proceeds. Upon selling the shares at $9.02, the Chief Executive Officer now owns 0 shares.
Before that, Gibson Christopher sold 40,000 shares. Recursion Pharmaceuticals Inc shares valued at $353,600 were divested by the Chief Executive Officer at a price of $8.84 per share. As a result of the transaction, Gibson Christopher now holds 978,524 shares, worth roughly $8.81 million.
Morgan Stanley initiated its Recursion Pharmaceuticals Inc [RXRX] rating to an Equal-weight in a research note published on May 22, 2023; the price target was $8. A number of analysts have revised their coverage, including Needham’s analysts, who began to cover the stock in mid March with a ‘”a Buy”‘ rating. KeyBanc Capital Markets began covering RXRX with “an Overweight” recommendation on September 16, 2022. BofA Securities revised its rating on April 18, 2022. It rated RXRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of RXRX
On Monday, Recursion Pharmaceuticals Inc [NASDAQ:RXRX] saw its stock jump 1.47% to $9.00. Over the last five days, the stock has lost -3.95%. Recursion Pharmaceuticals Inc shares have fallen nearly -8.72% since the year began. Nevertheless, the stocks have risen 39.53% over the past one year. While a 52-week high of $16.75 was reached on 02/27/24, a 52-week low of $4.54 was recorded on 04/05/24. SMA at 50 days reached $10.94, while 200 days put it at $9.31. A total of 3.12 million shares were traded, compared to the trading of 6.05 million shares in the previous session.
Levels Of Support And Resistance For RXRX Stock
The 24-hour chart illustrates a support level at 8.82, which if violated will result in even more drops to 8.64. On the upside, there is a resistance level at 9.15. A further resistance level may holdings at 9.30. The Relative Strength Index (RSI) on the 14-day chart is 37.21, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.96, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 80.59%. Stochastics %K at 10.91% indicates the stock is a buying.
How much short interest is there in Recursion Pharmaceuticals Inc?
A steep rise in short interest was recorded in Recursion Pharmaceuticals Inc stocks on Mar 15, 2024, growing by 5.28 million shares to a total of 43.52 million shares. Yahoo Finance data shows the prior-month short interest on Feb 15, 2024 was 38.24 million shares. There was a rise of 12.13%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 27.85% of the overall stock float, the days-to-cover ratio (short ratio) rose to 4.45.
